Display Settings:

Format

Send to:

Choose Destination
Steroids. 2011 Jul;76(8):750-2. doi: 10.1016/j.steroids.2011.02.023. Epub 2011 Mar 21.

Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors.

Author information

  • 1Siteman Comprehensive Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. cma@dom.wustl.edu

Abstract

Endocrine therapy has been the most effective treatment modality for hormone receptor positive breast cancer. However, its efficacy has been limited by either de novo or acquired resistance. Recent data indicates that activation of the phosphatidylinositol 3-kinase (PI3K) signaling is associated with the poor outcome luminal B subtype of breast cancer and accompanied by the development of endocrine therapy resistance. Importantly, inhibition of PI3K pathway signaling in endocrine resistant breast cancer cell lines reduces cell survival and improves treatment response to endocrine agents. Interestingly, mutations in PIK3CA, the alpha catalytic subunit of the class IA PI3K, which renders cells dependent on PI3K pathway signaling, is the most common genetic abnormality identified in hormone receptor positive breast cancer. The synthetic lethality observed between estrogen deprivation and PI3K pathway inhibition in estrogen receptor positive (ER+) breast cancer cell lines provides further scientific rational to target both estrogen receptor and the PI3K pathway in order to improve the outcome of ER+ breast cancer.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21420991
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk